Join our daily newsletter At The Bell to receive exclusive market insights
- Neuren Pharmaceuticals (NEU) receives a Notice of Allowance from the US Patent and Trademark Office for NNZ-2591 to treat autism
- The patent is titled “Bicyclic compounds and methods for their use in treating autism” and extends to July 2034
- Neuren is currently developing NNZ-2591 to treat a range of serious lifelong neurological disorders
- The aim of NNZ-2591 is to mimic the normal function of the brain and help control and normalise the biological process
- Shares in Neuren are up 3.48 per cent on the market and are trading at $2.08 at 1:57 pm AEDT
Neuren Pharmaceuticals (NEU) has received a Notice of Allowance from the US Patent and Trademark Office for NNZ-2591 to treat autism.
The patent is titled “Bicyclic compounds and methods for their use in treating autism” and extends to July 2034.
Neuren is currently developing NNZ-2591 to treat Phelan-McDermid, Angelman, Prader-Willi and Pitt Hopkins syndromes, all of which are serious lifelong neurological disorders.
The aim of NNZ-2591 is to mimic the normal function of the brain and help control and normalise the biological process.
CEO Jon Pilcher is excited by the granting of the patent as it could help understand autism in the United States.
“We have seen that the mechanism of action of NNZ-2591 appears to have broad utility in neurodevelopmental disorders,” Mr Pilcher said.
“Given that autism is estimated to affect one in 160 children, the granting of this important US patent could potentially enable a very large future opportunity as more becomes known about the causes of autism.”
Shares in Neuren were up 3.48 per cent on the market and were trading at $2.08 at 1:57 pm AEDT.
